Drug Type Small molecule drug |
Synonyms 6-(4-(1,1-Dimethylethyl)Phenoxy)-3-Pyridinamine, CB 103, CB-103 + [1] |
Target |
Action inhibitors |
Mechanism NOTCH1 inhibitors(Neurogenic locus notch homolog protein 1 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (European Union) |
Molecular FormulaC15H18N2O |
InChIKeyWHIWGRCYMQLLAO-UHFFFAOYSA-N |
CAS Registry218457-67-1 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Large Granular Lymphocytic Leukemia | Phase 2 | United States | 06 Apr 2023 | |
| T-cell acute lymphoblastic leukemia in relapse | Phase 2 | United States | 06 Apr 2023 | |
| Advanced breast cancer | Phase 2 | Spain | 06 May 2021 | |
| Adenoid Cystic Carcinoma | Phase 2 | United States | 05 Dec 2017 | |
| Adenoid Cystic Carcinoma | Phase 2 | France | 05 Dec 2017 | |
| Adenoid Cystic Carcinoma | Phase 2 | Germany | 05 Dec 2017 | |
| Adenoid Cystic Carcinoma | Phase 2 | South Korea | 05 Dec 2017 | |
| Adenoid Cystic Carcinoma | Phase 2 | Spain | 05 Dec 2017 | |
| Adenoid Cystic Carcinoma | Phase 2 | Switzerland | 05 Dec 2017 | |
| Colorectal Cancer | Phase 2 | United States | 05 Dec 2017 |
Phase 2 | 2 | disgctsglo = fnkxegvqxf ujtgganqtk (qybectczhl, kmkdiiaagu - cczljzwgsw) View more | - | 26 Nov 2025 | |||
Phase 1 | 41 | szzjvltpoz(aamvsvuisn) = One DLT (asymp ~ matic grade (G) 3 GGT increase) was observed at the highest dose (600mg). lmadqviumb (ugxvaplqrb ) View more | Positive | 28 May 2021 |





